Nothing Special   »   [go: up one dir, main page]

MXPA06000785A - Compuestos azapoliciclicos condensados con heteroarilo que reducen la adiccion a la nicotina. - Google Patents

Compuestos azapoliciclicos condensados con heteroarilo que reducen la adiccion a la nicotina.

Info

Publication number
MXPA06000785A
MXPA06000785A MXPA06000785A MXPA06000785A MXPA06000785A MX PA06000785 A MXPA06000785 A MX PA06000785A MX PA06000785 A MXPA06000785 A MX PA06000785A MX PA06000785 A MXPA06000785 A MX PA06000785A MX PA06000785 A MXPA06000785 A MX PA06000785A
Authority
MX
Mexico
Prior art keywords
alkyl
reducing
ch2ch2
hydrogen
nicotine addiction
Prior art date
Application number
MXPA06000785A
Other languages
English (en)
Inventor
Christopher John O'donnell
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MXPA06000785A publication Critical patent/MXPA06000785A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)

Abstract

La presente invencion proporciona un compuesto que tiene la estructura de formula I (ver formula I): en la que R1 es hidrogeno, alquilo (C1-C6), alquenilo (C3-C6) no conjugado, bencilo, YC(=O)-alquilo (C1-C6) o -CH2CH2-O-alquilo (C1-C4); X es CH2 o CH2CH2; Y es alquileno (C2-C6); Z es (CH2)m, CF2 o C(=O), donde m es 0, 1 o 2; R2 y R3 se seleccionan independientemente entre hidrogeno, halogeno, -alquilo (C1-C6) opcionalmente sustituido con 1 a 7 atomos de halogeno y -O-alquilo (C1-C6) opcionalmente sustituido con 1 a 7 atomos de halogeno, o cada uno de R2 y R3 junto con el atomo al que esta conectado forma independientemente C(=O), S?O, S(=O)2 o N?O; y (Het) es un grupo heteroarilo monociclico de 5 a 7 miembros seleccionado entre los grupos piridinilo, piridona, piridazinilo, imidazolilo, pirimidinilo, pirazolilo, triazolilo, pirazinilo, furilo, tienilo, isoxazolilo, tiazolilo, oxazolilo, isotiazolilo, pirrolilo, cinolinilo, triazinilo, oxadiazolilo, tiadiazolilo y furazanilo.
MXPA06000785A 2003-07-21 2004-07-08 Compuestos azapoliciclicos condensados con heteroarilo que reducen la adiccion a la nicotina. MXPA06000785A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48876003P 2003-07-21 2003-07-21
PCT/IB2004/002261 WO2005007655A1 (en) 2003-07-21 2004-07-08 Nicotine addiction reducing heteroaryl fused azapolycyclic compounds

Publications (1)

Publication Number Publication Date
MXPA06000785A true MXPA06000785A (es) 2006-04-18

Family

ID=34079453

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06000785A MXPA06000785A (es) 2003-07-21 2004-07-08 Compuestos azapoliciclicos condensados con heteroarilo que reducen la adiccion a la nicotina.

Country Status (10)

Country Link
US (1) US7456177B2 (es)
EP (1) EP1648893B1 (es)
JP (1) JP2006528169A (es)
AT (1) ATE443705T1 (es)
BR (1) BRPI0412712A (es)
CA (1) CA2529193A1 (es)
DE (1) DE602004023299D1 (es)
ES (1) ES2331245T3 (es)
MX (1) MXPA06000785A (es)
WO (1) WO2005007655A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
ES2708552T3 (es) 2002-12-20 2019-04-10 Niconovum Ab Método para la preparación de un material particulado que contiene nicotina con una celulosa cristalina (en particular MCC)
US7094572B2 (en) * 2003-03-14 2006-08-22 Bristol-Myers Squibb Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74
WO2006041773A2 (en) * 2004-10-04 2006-04-20 Millennium Pharmaceuticals, Inc. Lactam compounds useful as protein kinase inhibitors
US7923465B2 (en) * 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
EP1998748B1 (en) 2006-03-16 2015-01-14 NicoNovum AB Improved snuff composition
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
CL2008003749A1 (es) 2007-12-17 2010-01-15 Janssen Pharmaceutica Nv Compuestos derivados de imidazol, oxazol, y tiazol pirimidina, moduladores de trpv1, proceso de preparacion, composicion farmaceutica y su uso en el tratamiento de enfermedades, trastornos o condicion de dolor, prurito, artritis, tos, asma, trastorno del oido interno y enfermedad inflamatoria intestinal, entre otras.
JP5684719B2 (ja) 2008-12-05 2015-03-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｐｌｋ阻害剤としての５，７−ジヒドロ−６ｈ−ピリミド［５、−４ｄ］［１］ベンゾアゼピン−６−チオン
KR20120118497A (ko) * 2010-02-10 2012-10-26 조지아 테크 리서치 코포레이션 할로겐화 헤테로방향족의 재배열에 이은 산화커플링 반응에 의한, 커플링된 헤테로아릴 화합물의 제조 방법
CN104193612B (zh) * 2014-08-12 2016-03-02 深圳市道尔顿电子材料有限公司 一种2,3,5-三羧基环戊基乙酸的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235734B1 (en) 1996-10-30 2001-05-22 Pfizer Inc Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and their use in addiction therapy
US6020335A (en) 1997-02-06 2000-02-01 Pfizer Inc (N-(pyridinylmethyl)-heterocyclic)ylideneamine compounds as nicotinic acetylcholine receptor binding agents
EP1659114A3 (en) 1997-12-31 2007-01-17 Pfizer Products Inc. Process for the preparation of bicyclo[3.2.1]octane fused with quinazoline derivatives
ID26700A (id) 1998-04-29 2001-02-01 Pfizer Prod Inc Senyawa-senyawa azapolisiklik yang bercampur dengan aril

Also Published As

Publication number Publication date
BRPI0412712A (pt) 2006-09-26
ES2331245T3 (es) 2009-12-28
US7456177B2 (en) 2008-11-25
DE602004023299D1 (de) 2009-11-05
EP1648893B1 (en) 2009-09-23
CA2529193A1 (en) 2005-01-27
US20050020830A1 (en) 2005-01-27
WO2005007655A1 (en) 2005-01-27
JP2006528169A (ja) 2006-12-14
ATE443705T1 (de) 2009-10-15
EP1648893A1 (en) 2006-04-26

Similar Documents

Publication Publication Date Title
US8349842B2 (en) Therapeutic agents useful for treating pain
MXPA06000785A (es) Compuestos azapoliciclicos condensados con heteroarilo que reducen la adiccion a la nicotina.
EP1893212B1 (en) Multicyclic compounds and methods of their use
US7279493B2 (en) Therapeutic agents useful for treating pain
CN101384554B (zh) 吡啶-2-甲酰胺衍生物
CA2599974C (en) Pyridine-2-carboxamide derivatives as mglur5 antagonists
WO2005004866A1 (en) Therapeutic agents useful for treating pain
EA200800815A1 (ru) 2-анилин-4-арилзамещенные тиазольные производные
DE69434721D1 (de) Pharmacologisch wirksame pyrimidinderivate und verfahren zu deren herstellung
WO2005030753A2 (en) Therapeutic agents useful for treating pain
WO2004011441A1 (en) Pyridazinylpiperazine derivatives for treating pain
EP1664041A1 (en) Phenyl-carboxamide compounds useful for treating pain
EP2136805A2 (en) Piperidinyl-piperidine and piperazinyl-piperidine for use in the treatment of diabetes or pain
KR20070107101A (ko) ｍＧｌｕ５ 길항제로서 피라진-2-카복사미드 유도체
CA2739490A1 (en) Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof
US20100256111A1 (en) Therapeutic agents useful for treating pain
TW200619197A (en) Compounds which potentiate glutamate receptor and uses thereof in medicine
AU2009300316A1 (en) Compounds for inflammation and immune-related uses
CA2539297A1 (en) Substituted triazole derivatives as oxytocin antagonists
JP5902299B2 (ja) Ｐａｒｐ−１阻害剤としての３−オキソ−２，３−ジヒドロ−１ｈ−インダゾール−４−カルボキサミド誘導体
TW486478B (en) Pyrazole derivatives exhibiting anti-tumor effects and a pharmaceutical composition comprising the same
JPH02180881A (ja) チアゾール誘導体
CA2700963A1 (en) Oxypiperidine derivatives and methods of use thereof
KR20050021359A (ko) 통증 치료에 유용한 피페라진 유도체 치료제
MX9709150A (es) Nueva aplicacion de los derivados del pirrol.

Legal Events

Date Code Title Description
FG Grant or registration